Clerk of the House of Representatives	Secretary of the Senate
Legislative Resource Center	Office of Public Records
B-106 Cannon Building	232 Hart Building
Washington, DC 20515	Washington, DC 20510

Secretary of the Senate
Received: Aug 10, 2007

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

HOFFMANN-LA ROCHE

2. Address:
1425 K STREET, NW, #650, WASHINGTON, DC 20005

3. Principal place of business (if different from line 2):

4. Contact Name: SHANNON C. STEWARD
Telephone: 2024080090
E-mail (optional): shannon.cottrell-steward@roche.com

Senate ID #: 18411-12
House ID #:

7. Client Name: ☒ Self

TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): ☒ **OR** Year End (July 1 - December 31): ☐

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than $10,000: ☐

$10,000 or more: ☐ => Income (nearest $20,000):_____

Provide a good faith estimate, rounded to the nearest $20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than $10,000: ☐

$10,000 or more: ☒ => Expenses (nearest $20,000): 3,255,038.00

14. Reporting Method.
Check box to indicate expense accounting method. See instructions for description of options.

☒ **Method A.** Reporting amounts using LDA definitions only
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

Labor, HHS and Education Appropriations related to preparedness for pandemic influenza, HIV/AIDS programs and HCV screening, care and treatment.

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GARDNER, DARIN
Covered Official Position (if applicable): DIRECTOR, FGA
Name: MORRIS, EVAN
Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FGA
Name: SAGELY, ANNA
Covered Official Position (if applicable): DIRECTOR, FGA

19. Interest of each foreign entity in the specific issues listed on line 16 above.**None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

Copyright, Intellecutual Property and patent/trademark issues, lobbying for patent reform. Oppose importation of unsafe drugs from outside the U.S. Oppose amendments to weaken the Drug Price Competition and Patent term Restoration Act. Support uniform enforcement of U.S. patent laws. Monitor consideration of S.1145 and H.R. 1908, the Patent Reform Act of 2005. Support amendment to the bills.

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GARDNER, DARIN
Covered Official Position (if applicable): DIRECTOR, FGA
Name: MORRIS, EVAN
Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FGA
Name: SAGELY, ANNA
Covered Official Position (if applicable): DIRECTOR, FGA

19. Interest of each foreign entity in the specific issues listed on line 16 above.**None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

of osteoporosis drugs (Boniva); H.R. 1293/S.1338: Access to Medicare Imaging Act of 2007; coverage of immunosuppressive drugs; implementation of and appropriations related to P.L. 108-216: Organ Donation and Recovery Improvement Act Transplant-related legislation; H.R. 3043/S.1710: FY2007 Labor/HHS/Education Appropriations; H.R. 710 Charlie W. Norwood Living Organ Donation Act; H.R. 2808 - Living Organ Donor Job Security Act of 2007; H.R. 1035-Living Organ Donor Tax Credit Act of 2007; H. Res 555 - Supporting the goals and ideals of National Minority Donor Awareness Day; P.L. 109-423: Tax Relief and Health Care Act of 2006; P.L. 109-415: Ryan White HIV/AIDS Treatment Modernization Act of 2006; H.R. 2552/S. 1445: Senate and House versions of Hepatitis C Epidemic Control and Prevention Act; S. 1893: Children's Health Insurance Program Reauthorization Act of 2007; H.R. 3162: Children's Health and Medicare Protection Act of 2007; H.R. 1193/S. 691: Kidney Care and Quality and Improvement Act; Early treatment for HIV Act, legislation on public health preparedness and respone related to pandemic influenza; prescription drug coverage and reimbursement issues; allied health for veterans for diabetes care. Healthcare reimursement issues, pandemic preparedness and CMS; Labor HHS, Tamiflu, Community relations and outreach - develop and maintain relationships with minority groups and health organizations to highlight the potential benefits of a competitive anemia drug on the market such as MIRCERA; promoting initiatives and strategizing on the most effective approaches to explain Roche's efforts to address and try to resolve health disparities affecting minority communities; coverage of cancer drugs; coverage

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GARDNER, DARIN
Covered Official Position (if applicable): DIRECTOR, FGA
Name: MORRIS, EVAN
Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FGA
Name: SAGELY, ANNA
Covered Official Position (if applicable): DIRECTOR, FGA
Name: SCOTT, JAMES
Covered Official Position (if applicable): DIRECTOR, FGA

19. Interest of each foreign entity in the specific issues listed on line 16 above.**None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

Oppose importation of unsafe drugs from outside the US, Oppose efforts to put inappropriate restrictions or limitations on the prescription drug Accutane.

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: MORRIS, EVAN
Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FGA
Name: SAGELY, ANNA
Covered Official Position (if applicable): DIRECTOR, FGA

19. Interest of each foreign entity in the specific issues listed on line 16 above.**None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Support the promulgation of appropriate regulations under the Medicare Prescription Drug Act; reimbursement issues

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: GARDNER, DARIN
Covered Official Position (if applicable): DIRECTOR, FGA
Name: MORRIS, EVAN
Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FGA
Name: SAGELY, ANNA
Covered Official Position (if applicable): DIRECTOR, FGA

19. Interest of each foreign entity in the specific issues listed on line 16 above.**None**

Signature: ON FILE Date: Aug 10, 2007

Printed Name and Title: EVAN L. MORRIS, EXECUTIVE DIRECTOR, FEDERAL GOVERN -

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Aug 10, 2007

Printed Name and Title: -